Velenje

Researchers are investigating the real-world effectiveness of a fixed triple inhaled combination therapy in adults with asthma who remain uncontrolled despite previous treatments. This non-interventional, prospective study focuses on Trimbow 172/5/9 bcg, which combines beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium. While previous randomized trials demonstrated the safety and efficacy of such triple therapies in selected patients, this study aims to assess symptom improvement and treatment adherence in a broader clinical setting over six months. Participants will receive Trimbow 172/5/9 bcg via a pressurized metered-dose inhaler at a recommended dose of two inhalations twice daily. The study includes three visits: enrollment (baseline), one month after enrollment, and six months after enrollment. Patients must have switched to Trimbow no more than one week before or on the day of study inclusion. If treatment changes during the study, patients will be excluded from further participation. During the visits, researchers will collect demographic data, asthma history, lung function, symptom assessments using the Asthma Control Test (ACT), adherence questionnaires, and medication use. The main outcomes measured are improvements in ACT scores and the proportion of patients achieving a clinically important improvement after six months. Secondary outcomes include lung function and treatment adherence. The study plans to enroll 200 patients and expects to complete data collection by June 2026.